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Abstract
Healthy subjects frequently report minor bleedings that are frequently ‘background noise’ of normality rather than a true disorder.
Nevertheless, unexpected or unusual bleedingmaybealarming. Thus, the distinction betweennormal andpathologic bleeding is critical.
Understanding the underlying pathologic mechanism in patients with an excessive bleeding is essential for their counseling and
treatment.Most of these patientswith signiﬁcant bleedingwill result affectedbynon-severe inheritedbleedingdisorders (BD), collectively
denominated mild or moderate BD for their relatively benign course. Unfortunately, practical recommendations for the management of
thesedisorders are still lacking due to the current state of fragmented knowledge of pathophysiology and lack of a systematic diagnostic
approach. To address this gap, an International Working Group (IWG) was established by the European Hematology Association (EHA)
to develop consensus-based guidelines on these disorders. The IWG agreed that grouping these disorders by their clinical phenotype
under the single category of mild-to-moderate bleeding disorders (MBD) reﬂects current clinical practice and will facilitate a systematic
diagnostic approach. Based on standardized and harmonized deﬁnitions a conceptual uniﬁed framework is proposed to distinguish
normal subjects fromaffectedpatients. The IWGproposes aprovisional comprehensivepatient-centered initial diagnostic approach that
will result in classiﬁcation ofMBD into distinct clinical-pathological entities under the overarching principle of clinical utility for the individual
patient.While wewill present here a general overviewof the global management of patientswithMBD, this conceptual frameworkwill be
adopted and validated in the evidence-based, disease-speciﬁc guidelines under development by the IWG.
The authors have indicated they have no potential conﬂicts of interest to disclose.
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Introduction
The hemostatic system maintains blood ﬂuidity while reducing
the risk of bleeding or thrombosis through a ﬁnely tuned and
integrated interplay of an intact vasculature and its endothelium
with platelets, blood coagulation and ﬁbrinolysis. In principle,
any genetic abnormality in any component - the function of
which could not be fully replaced by the redundancy of the system
- will appear phenotypically as a tendency towards excessive
bleeding or a thrombotic risk. Minor bleeding manifestations,
although often alarming, are common in otherwise healthy
people who can sustain major hemostatic challenges without
danger.1,2 However, they may be also indicative of several
pathophysiologically-deﬁned bleeding disorders (BDs) character-
ized by a mild or moderate bleeding tendency. During the past
decades, as a result of progress in laboratory and genetic
diagnosis, an increasing number of such BDs has been described.
Inherited BDs may be due to quantitative or qualitative defects
of one or more of the components of the hemostatic system or
vessel wall collagen and other matrix components, and have been
referred to as mild or mild/moderate bleeding disorders, using the
acronym MBD.3–8 Currently, the screening and diagnosis of
inherited MBDs remain challenging and the assessment of the
magnitude of future bleeding risk and of the burden of these
disorders on quality of life (QoL) have been poorly investigated,
apart from the few studies in adults with VWD9 and in women
with heavy menstrual bleeding as their dominant symptom.10
Hence, screening and diagnostic work up of patients for a
suspected MBD tend to be based on local practices rather than
guided by sound clinical, laboratory or genetic criteria.
To address this gap, the European Hematology Association
(EHA) established an International Working Group (IWG) to
develop a series of guidelines on MBDs. The IWG agreed to
maintain this acronym, where M stands for “mild to moderate”
to encompass the wide variation of bleeding phenotypes to
indicate an overall milder bleeding phenotype when contrasted to
the more rare severe hemostatic disorders that, if untreated, may
cause life- or organ-threatening hemorrhages.
The aim of this ﬁrst communication is to deﬁne the basis of a
systematic, uniform approach to MBDs and to provide a
consensus on the principles underlying the following guidelines
that will be speciﬁcally dedicated to: non-type 3 von Willebrand
Disease; Coagulation and ﬁbrinolytic system disorders; Platelet
and vascular disorders; Bleeding of unknown cause.
The IWG agreed that these guidelines should assure clinical
utility in terms of a real beneﬁt for the patient and/or family
members while simultaneously helping physicians to exclude
false positive or useless diagnoses, thereby avoiding the risk that
healthy subjects become disadvantaged by the stigma of a
hereditary disorder while providing guidance for the manage-
ment of those conﬁrmed to have MBDs.
At the same time, the IWG is well aware that current diagnostic
technologies suffer from major limitations and that the genetic
approach is increasingly used but still in development, so that
areas of future research should be identiﬁed.
Methodology
The IWG included 20 members selected for their recognized
expertise in research and clinical practice, with consideration of a
wide geographic representation to provide an international
perspective. EHA veriﬁed the absence of relevant competing
conﬂict of interests of the IWG and supervised the project with
regard to compliance to, and consistency with, the methodology
adopted by its Committee on Guidelines. EHA provided
organizational and logistic assistance and funding for face-to-
face meetings or teleconferences.
The IWG agreed to hereby present a self-standing introductory
paper on the various methodological aspects for the deﬁnition
and classiﬁcation of inherited MBDs, and for a standardized
approach to diagnosis andmanagement.With this background, a
series of disorder-speciﬁc evidence-based guidelines will be
produced using a Delphi-like approach when evidence-based
recommendations could not be derived from a systematic
literature review. For this preliminary document, it was agreed
that a systematic review of literature was not necessary.
However, to share a common domain of knowledge, the IWG
coordinator (FR) made available an initial list of references
dealing with MBDs or with the general principles that should
guide a diagnostic and management process. A provisional list of
potential candidate MBDs was also proposed to represent a
concrete domain for discussion and analysis and to facilitate the
planning of future disease-speciﬁc guidelines and related
systematic literature review (Supplemental Table 1, Supplemental
Digital Content, http://links.lww.com/HS/A43). As explained in
the footnote to Supplemental Table 1, this provisional list should
in no way be intended as a list of established MBDs. After
agreement on the main scope and structure of the document, a
consensus was progressively reached through an iterative
process, guided in a no-directive way by the coordinator of
the panel. This process required at least 10 rounds of progressive
drafts circulated among all IWG members highlighting all
amendments and suggestions. In addition to electronic
exchanges, three face-to-face meetings were held in conjunction
with EHA or ASH meetings from 2016 to 2018 and a ﬁnal
conference call was made. Finally, the submitted version was
unanimously approved by all authors.
Deﬁnition of MBDs: clinico-pathological
criteria and proposal for standardization
A bleeding phenotype sufﬁciently distinctive to be considered
as a disease status, but of much less severity in comparison to
severe bleeding disorders, was taken as the major unifying
factor of MBDs. Representative examples are patients with
type 1 VWD; mild or moderate hemophilia or hemophilia
carriers; heterozygous deﬁciencies of speciﬁc clotting factors;
deﬁciency of ﬁbrinolysis inhibitors or some quantitative and/
or qualitative platelet disorders. In contrast, a distinctly severe
phenotype was considered to be associated with severe
hemophilia, type 3 VWD, some homozygous recessive
coagulation defects or some platelet function defects such
as biallelic Glanzmann Thrombasthenia (GT) and Bernard-
Soulier syndrome. However, apart from these and a few other
examples, the IWG acknowledged the lack of a precise
deﬁnition delimiting the MBD category. Indeed, we still do
not have consensus on the explicit clinical criteria for making
decisions, due to the continuous spectrum of increasing
severity from normal subjects to those with mild/moderate
and severe disorders. The IWG agreed that combining these
disorders under the single, although imperfect, category of
MBDs, together with a standardization of deﬁnitions and
terminology will facilitate ongoing efforts to streamline a
systematic approach to these disorders and to develop
comprehensive and reliable diagnostic algorithms that result
in optimal management strategies.
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Notably, the grouping of MBDs is based more on bleeding
phenotype than on laboratory or genetic features, although it is
acknowledged that this grouping does not point to a speciﬁc
diagnosis, nor does it generally predict the risk of future bleeding.
Indeed, only distinct mechanistic characteristics, as revealed by
laboratory or genetic investigations, confer disease speciﬁcity to
the different MBDs, thus substantially contributing more
appropriately to management and counseling. Accordingly, the
IWG adopted clinico-pathologic criteria to classify MBDs as
distinct disease entities, qualiﬁed by a unique set of hemostatic
and/or genetic abnormalities (Table 1).
However, we acknowledge that a sizable proportion of
patients without any demonstrable underlying hemostatic or
genetic abnormalities may have a bleeding phenotype as severe as
patients with an established MBD, in whom a speciﬁc laboratory
or genetic diagnosis is apparent. These subjects are commonly
classiﬁed as BUC (bleeders/bleeding of unknown cause).11
Clinical aspects: deﬁnition of bleeding phenotype
The IWG agreed to use the standardized deﬁnitions of 14 distinct
symptoms and their severity scale (from 1 to 4) adopted in the
Bleeding Assessment Tool (BAT) endorsed by the International
Society on Thrombosis and Haemostasis (ISTH).12
Bleeding symptoms deﬁnition and severity-based clas-
siﬁcation
The ISTH-BAT makes a clear distinction between “trivial”
bleeding, that should not be considered, and “true” bleeding
manifestations, which may be representative of a disease and
that, according to their severity, are scored in the range of 1 to 4.
Minimal criteria for deﬁning a bleeding symptom as signiﬁcant
(non-trivial) and the relative score according to the ISTH-BAT
scale are shown in Tables 2 and 3 (adapted from Rodeghiero
et al12). The recommended deﬁnitions and terminology for
describing the severity of bleeding symptoms and of bleeding
phenotypes are shown in Table 4. Since the frequency of bleeding
is not accounted for as a primary grading factor by the ISTH-
BAT, we have introduced a new category of nuisance bleeding to
account for patients suffering from frequent and disturbing
bleeding symptoms that, individually, could be considered trivial.
This category has been borrowed from deﬁnitions proposed for
patients treated with antithrombotic therapy13,14 to describe
bleeds that impact patient QoL for their frequency and recurrence
(Table 4).15
While some modiﬁcations in grading the bleeding symptoms
have been proposed to improve the utility of the ISTH-BAT,16 the
IWG members agreed that they do not have any relevant impact
on the description and classiﬁcation of bleeding symptom
severity, provided that only episodes before diagnosis are
considered.
With this caveat, the ISTH-BAT can also be used for the
investigation of family members, recognizing that the bleeding
phenotype can be highly variable even in family members
carrying the same genetic defect. It would be desirable to extend
the investigation beyond ﬁrst-degree relatives, but we acknowl-
edge that this is often not possible and raises questions about
privacy. The propositus, or parents, may be encouraged to
approach other family members beyond ﬁrst-degree.
Table 1
Deﬁnition of Inherited/Congenital Bleeding Disorders (BD), Bleeders of Unknown Cause (BUC) and Other Conditionsa,b
Bleeding disorder (BD) Any distinct disease entity associated with excessive bleeding tendency (with or without visible physical
manifestations) and qualiﬁed by a unique set of hemostatic and/or genetic abnormalities (clinico-pathologic
classiﬁcation)
Mild to moderate bleeding disorder (MBD) Denomination used to collectively describe any BD associated with a mild to moderate bleeding phenotype. The
bleeding phenotype is often not distinctively manifest or predictable at the time of diagnosis. It may become
evident later in life or only after signiﬁcant hemostatic challenges. Most diseases discussed in this document
belong to this group. A typical example may be VWD.
Mild BD: Any BD consistently associated with a mild bleeding phenotype in the great majority of affected, present at
the time of diagnosis or reasonably predictable. Examples: mild hemophilia A and B (FVIII or FIX > 5% and <
40%); some disorders with a reduced platelet count and/or function defects.
Moderate BD: Any BD consistently associated with a moderate bleeding phenotype in the great majority of the
affected. The bleeding phenotype may be already manifest at the time of diagnosis or become evident later in life
or after signiﬁcant hemostatic challenges. Examples: moderate hemophilia A and B (FVIII or FIX between 1% and
5%); some disorders with a reduced platelet count and/or function defects.
Severe bleeding disorder (SBD) Excessive bleeding tendency characterized by the occurrence of at least one symptom with score 4, according to
the ISTH BAT, Table 3). Organ or life-threatening bleeding episodes requiring hospitalization or in-hospital
procedures to control bleeding may be present at variable frequency, but could be rare. Fatal hemorrhage may
occur or be reported in family members. Spontaneous bleeding with mild or moderate severity may be more or
less frequent but almost invariably present after major hemostatic challenges including surgery and invasive
procedures. Early onset in life is common. Bleeding manifestations usually include also many symptoms with
score 1 to 3. Examples: complete deﬁciency of speciﬁc pro-coagulant factors or co-factors of (complete FXIII
deﬁciency), GT, biallelic Bernard Soulier syndrome.
Bleeder/Bleeding of unknown cause (BUC) A BD ﬁtting the deﬁnition of mild/moderate bleeding phenotype (but even possibly severe in some rare cases) that
cannot be associated to any hemostatic or genetic abnormality after extensive investigation with currently
available techniques. It cannot be excluded that under this provisional category future novel techniques may
identify new disease entities.
Other conditions: heterozygous, double heterozygous,
homozygous, monoallelic, biallelic, carrier, combined
defects
Used to indicate different pathologic status deﬁned by genetic analysis or laboratory investigations, usually during
family members investigations, independently from the presence of bleeding. These subjects may or may not
have excessive bleeding tendency
a The terms used to describe genetically-determined disorders included various terms of overlapping signiﬁcance, but also with subtle differences in meaning: hereditary, inherited, heritable, congenital, inborn. We
will use as interchangeable the terms inherited or hereditary to emphasize the heritability of a disease, and congenital or inborn when the disease is present from birth, regardless of the causation.
b We should prefer bleeder when referring to a subject and bleeding when referring to a status but in practice this distinction can be omitted and use the same acronym.
(2019) 3:5 www.hemaspherejournal.com
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Notably, MBDs do not protect against the occurrence of
thrombotic events in speciﬁc clinical settings, as will be discussed
in speciﬁc guidelines.
Physical examinationandexclusionofacquiredconditions
Physical examination may be relevant for the detection of
particular signs such as petechiae on the skin or visible mucosal
bleeding, large ecchymoses in exposed areas (pointing to senile
purpura), hemarthrosis, joint hyperﬂexibility, facial or skeletal
anomalies or telangiectasia. To diagnose vascular disorders, the
Beighton score may be used to assess hypermobility.17 The
distribution and type of bleeding manifestations may raise the
suspicion of non–accidental injury (eg, child or adult battered
syndrome) or of psychogenic or self-inﬂicted (factitious) lesions
(eg, Munchausen syndrome), or bilateral periorbital purpura
(“raccoon eyes”) in AL amyloidosis. In addition, physical
examination and a comprehensive general clinical history could
help to exclude that bleeding is associated to acquired conditions
such as uremia, liver disease, Cushing syndrome, hypothyroid-
ism, hypertension and anemia, to name a few.
Laboratory and genetic aspects
Laboratory aspects
A detailed investigation of the laboratory phenotype beyond the
results of ﬁrst-stage investigation (Fig. 1) may indicate the
underlying pathogenic mechanism and, depending on the nature
of the disorder, guide treatment and, in some cases, be sufﬁciently
predictive of the patient’s future bleeding risk. FVIII or FIX
deﬁciencies may be the most representative examples since a good
correlation between the residual clotting activity and the bleeding
phenotype seems well established.18 So, the classical laboratory-
based distinction between severe, mild and moderate hemophilia
is still maintained in the literature and will be here adopted
(Table 1), even if it has been recently questioned, with a proposal
to move from a laboratory-based to a bleeding phenotype-based
classiﬁcation,19 or to a much more complex laboratory and
genetic investigation.20 Similarly, it remains questionable if
patients with a marginally low VWF level (between 30% and
50% of normal range) may have a signiﬁcant bleeding phenotype
as reﬂected by the ISTH-BAT score.21 In most MBDs laboratory
abnormalities might prove inconsistent in predicting the risk of
bleeding. The IWG agrees that in the absence of a qualifying
bleeding phenotype, it is inappropriate to consider subjects as
being affected by a MBD unless the qualifying laboratory assay
has a very high likelihood for a distinct disorder.
Genetic aspects
Even genetic abnormalities, now detectable on a massive scale,
cannot be invariably linked to a precise clinical and laboratory
phenotype. Cutting-edge technologies in genetics and genomics
may contribute to group disorders previously classiﬁed as distinct
entities into the same category or identify new disorders among
Table 2
Minimal Criteria Deﬁning a Bleeding Symptom as Signiﬁcant (non-trivial)
Type of bleeding Criteria (Based on ISTH-BAT)
Epistaxis Any nosebleed without identiﬁable cause resulting in interference or anxiety with daily or social activities. In general,
not be considered signiﬁcant when lasting less than 10 minutes and/or frequency of < 5 episodes/year
Cutaneous bleeding 5 or more ecchymoses (> 1cm) in exposed areas; petechiae when adequately described; hematomas occurring
without trauma
Minor cutaneous wound Any prolonged (> 10 min) bleeding episode caused by superﬁcial cuts (eg, by shaving razor, knife, or scissors) or
that requires frequent bandage change manifest on more than one occasion
Oral cavity bleeding Gum bleeding causing frankly bloody sputum lasting for 10 minutes or longer on more than one occasion. Bleeding
after bites to lips, cheek, and tongue if lasting at least 10 minutes or causing a swollen tongue or mouth
Tooth eruption or spontaneous tooth loss Requires assistance or supervision by a physician, or lasts at least 10 minutes
Tooth extraction Any bleeding occurring after leaving the dentist’s ofﬁce requiring a new, unscheduled visit or prolonged bleeding at
the dentist’s ofﬁce causing a delay in the procedure or discharge
Hematemesis, melena, and hematochezia Any bleeding not explained by the presence of a speciﬁc disease
Hematuria Macroscopic hematuria without identiﬁable cause or disease
Surgical bleeding Any bleeding judged by the surgeon to be abnormally prolonged, or causing a delay in discharge, or requiring some
supportive treatment
Heavy menstrual bleeding (menorrhagia) Any bleeding interfering with daily activities, such as work, housework, leisure or sport or social activities during most
menstrual periods. Anyway, bleeding is signiﬁcant if at least one of the following occurs: changing pads more
frequently than every 2 hours; menstrual bleeding lasting 7 or more days; presence of clots > 1cm combined with
a history of ﬂooding. PBACa score higher than 100
Primary PPH within 24hours of deliverya Blood loss of 500 ml or more from the genital tract, or blood loss that requires intervention such as the use of
additional uterotonics, tranexamic acid, blood or blood products or use of mechanical or surgical hemostatic
measures
Secondary PPH 24hours after delivery – 12
weeksa
Vaginal bleeding or uterine discharge (lochia) that lasts for more than 6 weeks. Any bleeding of lesser duration, that is
judged by the obstetrician, as abnormally heavy or prolonged or causes a delay in discharge or requires some
supportive treatment, or causes progressive anemia or requires changing pads or tampons more frequently than
every 2hours
Muscle hematomas or hemarthrosis Any spontaneous joint/muscle bleed (not related to traumatic injuries)
CNS bleeding Any subdural or intracerebral hemorrhage requiring diagnostic or therapeutic intervention is scored 3 or 4,
respectively.
Any infancy-speciﬁc bleeding symptoms See ISTH-BAT
Other symptoms Any intracranial hemorrhage and all neonatal bleedings
a Deﬁnitions based on Mavrides et al on behalf of the Royal College of Obstetricians and Gynecologists. Prevention and management of post-partum hemorrhage.72
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Table 3
Severity Score Assigned to Distinct Bleeding Symptoms According to the ISTH-BAT Scale, Only Episodes before Diagnosis should be
Considered
SCORE
SYMPTOMS (up to the
time of diagnosis) 0x 1x 2 3 4
Epistaxis No/trivial - > 5/year or
- more than 10 minutes
Consultation only
∗
Packing or cauterization or
antiﬁbrinolytic
Blood transfusion or replacement
therapy° or desmopressin
Cutaneous No/trivial For bruises 5 or more
(> 1cm) in exposed areas
Consultation only
∗
Extensive Spontaneous hematoma requiring
blood transfusion
Bleeding from minor
wounds
No/trivial - > 5/year or
- more than 10 minutes
Consultation only
∗
Surgical hemostasis Blood transfusion, replacement
therapy, or desmopressin
Oral cavity No/trivial Present Consultation only
∗
Surgical hemostasis or
antiﬁbrinolytic
Blood transfusion, replacement
therapy or desmopressin
GI bleeding No/trivial Present but not associated
with ulcer, portal hypertension,
hemorrhoids, angiodysplasia
Spontaneous Surgical hemostasis,
antiﬁbrinolytic
Blood transfusion, replacement
therapy or desmopressin
Hematuria No/trivial Present (macroscopic) Consultation only
∗
Surgical hemostasis, iron
therapy
Blood transfusion, replacement
therapy or desmopressin
Tooth extraction No/trivial or none done Referred in 25% of all
procedures, no intervention
∗∗
Referred in >25% of all
procedures, no
intervention
∗∗
Resuturing or packing Blood transfusion, replacement
therapy or desmopressin
Surgery No/trivial or none done Referred in 25% of all
procedures, no intervention
∗∗
Referred in >25% of all
procedures, no
intervention
∗∗
Surgical hemostasis or
antiﬁbrinolytics
Blood transfusion, replacement
therapy or desmopressin
Heavy menstrual bleeding
(Menorrhagia in the
original ISTH-BAT)
No/trivial Consultation only
∗
or
- Changing pads more frequently
than every 2 hours or
- Clot and ﬂooding or
- PBAC score>100
- Time off work/school >
2/year or
- Requiring antiﬁbrinolytics
or hormonal or iron
therapy
- Requiring combined
treatment with
antiﬁbrinolytics and
hormonal therapy or
- Present since menarche
and > 12 months
- Acute menorrhagia requiring
hospital admission and
emergency treatment or
- Requiring blood transfusion,
Replacement therapy,
Desmopressin, or
- Requiring dilatation & curettage
or endometrial ablation or
hysterectomy)
Post-partum hemorrhage No/trivial or
no deliveries
Consultation only
∗
or
- Use of syntocin or
- Lochia > 6 weeks
- Iron therapy or
- Antiﬁbrinolytics
- Requiring blood
transfusion, replacement
therapy, desmopressin
or
- Requiring examination
under anaesthesia and/
or the use of uterine
balloon/package to
tamponade the uterus
- Any procedure requiring critical
care or surgical intervention
(eg, hysterectomy, internal
iliac artery legation, uterine
artery embolization, uterine
brace sutures)
Muscle hematomas Never Post trauma, no therapy Spontaneous, no therapy Spontaneous or traumatic,
requiring desmopressin
or replacement therapy
Spontaneous or traumatic,
requiring surgical intervention
or blood transfusion
Hemarthrosis Never Post trauma, no therapy Spontaneous, no therapy Spontaneous or traumatic,
requiring desmopressin
or replacement therapy
Spontaneous or traumatic,
requiring surgical intervention
or blood transfusion
CNS bleeding Never – – Subdural, any intervention Intracerebral, any intervention
Other bleedings including
infancy-speciﬁc
symptomsf,^:
No/trivial Present Consultation only
∗
Surgical hemostasis,
antiﬁbrinolytics, iron
therapy
Blood transfusion or replacement
therapy or desmopressin
Score should be calculated on the basis of a standardized questionnaire administered by the investigator or by trained personnel (available at https://www.isth.org/page/reference_tools). Since having a speciﬁc
diagnosis in hand may induce a more liberal administration of prophylactic treatment, it is critical to understand that the ISTH-BAT was designed to score bleeding symptoms that were present at diagnosis.
Accordingly, use of desmopressin or clotting factor replacement therapy should be scored only if given prior to diagnosis of the propositus (or of the propositus’ family) to account for the decision taken by treating
physicians to administer these therapies before the diagnosis was established.
In addition to the guidance offered by the table, it is mandatory to refer to the text for more detailed instructions.
xDistinction between 0 and 1 is of critical importance. Score 1 means that the symptom is judged as present in the patient’s history by the interviewer, but does not qualify for a score 2 or more
∗
Consultation only: the patient sought medical evaluation and was either referred to a specialist or offered detailed laboratory investigation
°Replacement therapy may include speciﬁc hemostatic blood components and rFVIIa
∗∗
Example: 1 extraction/surgery resulting in bleeding (100%): the score to be assigned is 2; 2extractions/surgeries, 1 resulting in bleeding (50%): the score to be assigned is 2; 3 extractions/surgeries, 1 resulting
in bleeding (33%): the score to be assigned is 2; 4extractions/surgeries, 1 resulting in bleeding (25%): the score to be assigned is 1
#If already available at the time of collection
^Infancy-speciﬁc symptoms: umbilical stump bleeding, cephalohematoma, cheek hematoma caused by sucking during breast/bottle feeding, conjunctival hemorrhage, or excessive bleeding following
circumcision or venipuncture. Their presence or that of post-menarche menorrhagia requires detailed investigation independently from the overall score
(2019) 3:5 www.hemaspherejournal.com
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those previously considered the same entity. However, it remains
unproven if the non-targeted application of these technologies
will be of clinical utility in daily practice.
The phenotypic effects of genetic abnormalities may be
partially compensated or masked by the individual genetic
backgrounds. The clinical phenotype of most bleeding disorders
is rarely the result of a monogenic defect, but it is often inﬂuenced
by the interaction between different genes/polymorphisms and/or
between genetic and acquired factors. This complex genetic
interplay may aggravate or alleviate the severity of the bleeding
phenotype in general population.22 Interesting examples in
bleeding disorders may be found in variations in genes that affect
VWF levels including CLEC4M or STXBP523,24 or in the
presence of prothrombotic mutations, such as factor V Leiden
that may attenuate the phenotype of bleeding disorders such as in
hemophilia.25 Furthermore, the impact of a single mutation may
be even less predictable, as in the case of multi-subunit molecules
such as ﬁbrinogen or multimeric proteins such as vonWillebrand
factor (VWF). In these cases, depending on the particular genetic
defect, the variable inclusion of the abnormal subunit or
monomer into the ﬁnal product might produce a continuous
spectrum of residual activity from zero to the lower limit of
normal, so that in these instances the contribution of genetic
studies appears of limited practical relevance [eg, VWD]. Even
more complex is the diagnostic role of genetics in vascular
disorders or hereditary thrombocytopenias, with or without
additional functional defects and/or syndromic features. In some
of these patients, the incidental discovery of genetic mutations
may be associated with an increased future risk of hematological
malignancy.26
Bleeders of unknown cause
In a sizable proportion of patients with a qualifying bleeding
phenotype - and sometimes with a family history of bleeding - no
hemostatic or genetic abnormality can be found, even after an
extensive investigation. These cases have been variably referred
to as “bleeding/bleeders of unknown cause (BUC)”.4,11 While
currently BUC is meant to describe a true BD despite the absence
of distinct laboratory ﬁndings, with the improvement of
molecular characterization or of other laboratory technologies,
some previous BUC could receive a clinico-pathological diagno-
sis. For example, two such new autosomal dominant disorders
have been recently identiﬁed in large kindred with techniques or
measurements available only in dedicated research laborato-
ries:27 the ﬁrst caused by an abnormal short form of Factor V
associated with severe bleeding manifestations, in which APTT
and PT were prolonged but the levels of all known coagulation
factors were normal (East Texas bleeding disorder);28,29 the
second, associated with normal screening assays (but reduced
prothrombin consumption) caused by a novel mutation in the
thrombomodulin gene, which seems to ﬁt our deﬁnition of
MBD.30
Clinical utility should guide patients’
investigation
Diagnostic tests and procedures are justiﬁed only if a net health
beneﬁt for the patient is expected from such testing. Tests should
ﬁt the purpose and the context in which they are used.31 For
example, patients may be referred for speciﬁc circumstances such
Table 4
Recommended Deﬁnitions and Terminology for the Description of the Severity of Bleeding Symptoms and Associated Bleeding
Phenotypes
SYMPTOMSa
Severity Description
Nuisance bleeding Easy bleeding consisting in frequent (> 5 times/yr) bruising, nose, gum, mild menorrhagia or other minor hemorrhagic symptoms that
may be disturbing for the patient, although not causing the patient to seek medical care. The single bleeding manifestations would
have otherwise received score 0 to 1 with ISTH-BAT and the bleeding phenotype would not qualify for a BD.
Mild Any bleeding event that does not require speciﬁc intervention by a doctor beyond simple consultation or referral for investigation or
general education on admitted medications and life style or for initiation of a diagnostic procedure (score 1 or 2). Antiﬁbrinolytic and
hormonal/local IUD treatment for heavy menstrual bleeding or for post-partum hemorrhage might be required.
Moderate Any bleeding event that requires active medical intervention or treatment to control hemorrhage and does not exceed score 3. Subdural
hematoma not requiring treatment or prolonged observation is considered moderate symptom.
Severe Any bleeding requiring red blood cell transfusion or replacement treatment (plasma, platelet concentrates, coagulation factors) or hospital
based hemostatic procedures or hospitalization (score 4) Any CNS bleeding.
BLEEDING PHENOTYPEa
Severity Description
Mild bleeding phenotype Excessive bleeding tendency represented by more or less frequent mild bleeding symptoms that, despite being perceived as alarming by the
patient or patient family members, are not organ-threatening or fatal and do not require medical intervention (apart from referral for investigation
or general education on medications and life style). They may appear late in life. May be spontaneous (epistaxis), but are usually provoked by
signiﬁcant hemostatic challenges such as menstruation, dental extraction, surgery or trauma. The impact of the perceived QoL should be
reported but be minimal and no or minimally affecting daily life style. Bleeding episodes do not exceed score 2 ISTH-BAT.
Moderate bleeding phenotype Excessive bleeding tendency characterized by mild, but also by one or more moderate symptoms not exceeding score 3 ISTH-BAT. On the
overall the moderate bleeding phenotype is of intermediate severity. Single bleeding episodes may be spontaneous or secondary to
minimal trauma and may require speciﬁc medical intervention. Organ-threatening damage is possible, but rare and never fatal (apart in
economically deprived counties). In these patients, the frequency of bleeding symptoms is variable but they may occur at an early age
and should call for prompt investigation.
Severe bleeding phenotype Excessive bleeding tendency characterized by one or more score 4 ISTH-BAT symptoms. Abnormal bleeding may appear in the early
infancy or neonatal period. Parents and/or family members may be asymptomatic in case of recessive disorders or have a mild
bleeding phenotype in disorders with low penetrance and/or expressivity. Fatal events may occur if hemorrhage is not properly treated.
a In this document, bleeding symptom is generally used to indicate that in hereditary disorders, particularly for less severe cases, we rarely have the opportunity to directly observe bleeding events, instead wemust frequently rely
only on patients’ (or parents’, tutors’) description. When we explicitly want to refer to the clinician’s interpretation and description of referred symptoms, we will refer to them as bleeding manifestations.
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Assessment of BP: ISTH-BAT, nuisance bleeding and any bleeding in 
infancy integrated in a ﬁnal crical judgment considering physical
examinaon, family history, age, sex and co-morbidies
BP not qualifying for BD
Low probability of BD
ISTH BAT > 4 in males, > 6 in females, > 2 in 
children or any unusual bleeding in infancy$ or
nuisance bleeding
Standard screening
Platelet count and peripheral blood 
exam 
APTT§ and  PT/INR
Fibrinogen*
Consider VWF acvity in speciﬁc
circumstances^ 
1st stage invesgaons
Platelet count and peripheral 
blood examinaon
APTT§ and PT/INR
Fibrinogen
VWF acvity
Standard platelet 
aggregometry°
Tailored approach
Relaves of index case 
Pregnancy
High risk surgery
Emergency situaons
Heavy menstrual bleeding
Post-menarche hemorrhage
PPH
2nd stage invesgaons 
Speciﬁc approaches for:
VWD
Coagulaon and ﬁbrinolyc system disorders
Platelet number and funcon disorders
Vascular disorders
Exclude  irrelevant abnormality 
for bleeding risk like lupus 
ancoagulant or contact factor 
deﬁciencies
Based on the type of remaining 
abnormality, if any, consider 
reevaluaon, 2nd stage 
invesgaons or individual 
counseling
Innovave or research 
invesgaons
Paent referred for invesgaon of bleeding tendency
ISTH BAT < 4 in males, < 6 in 
females , < 2 in children
BP qualifying for BD
High probability of BD or BUC
Exclude  irrelevant abnormality for bleeding 
risk like lupus ancoagulant or contact factor 
deﬁciencies
Based on the type of remaining abnormality, 
if any, move to selected 2nd stage 
invesgaons for the relevant  category
Be aware  that FXIII deﬁciency and 
ﬁbrinolysis abnormalies are not detected 
Disnct BD BUC
FIGURE 1. A proposed diagnostic approach for patients referred for investigation of bleeding symptoms. Standard screening is performed in all referred
subjects to conﬁrm negative results of previous tests or to clarify any abnormalities detected. Patients with a qualifying bleeding phenotype should undergo 1st stage
investigations and, on the basis of the results, be directed to 2nd stage investigations, distinct for VWD, other coagulation and ﬁbrinolytic disorders and platelet
number/function disorders. Vascular disorders should be considered based on physical examination. Some tests could be anticipated and a full investigation
postponed under particular circumstances requiring a tailored approach. Patients with a doubtful history should undergo standard screening including, in particular
circumstances, measurement of VWF activity. A further stage including innovative and/or research investigations can be considered for BUC. All BD are considered
together in the diagnostic process, as it is intended to be appropriate as a general approach to patients at risk of bleeding. BP, bleeding phenotype; BD, bleeding
disorder; BUC, bleeding of unknown cause. Broken arrows indicate an alternative approach tailored for speciﬁc circumstances, as discussed in the text. $Includes:
umbilical stump bleeding, cephalohematoma, cheek hematoma caused by sucking during breast/bottle feeding, conjunctival hemorrhage, or excessive bleeding
following circumcision or venipuncture and post-menarche menorrhagia. xIf not sure that APTT is sensitive to FVIII and FIX < 40-50%, speciﬁc assays for FVIII and
FIX are required.
∗
Thrombin time can be used if ﬁbrinogen activity assay is not available or is not being used in the clinical laboratory. ^Low VWF level may be a risk
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as urgent preoperative screening; emergency circumstances in the
obstetric, surgical or trauma setting; incidental laboratory
ﬁndings or as relatives of a subject with a known hemostatic
disorder. From the global healthcare perspective, the concept of
clinical utility is embedded in the broader concept of value,
deﬁned as outcomes for the patient relative to the cost required to
produce them. This efﬁciency criterion - increasingly adopted by
healthcare delivery organizations - is endorsed by the IWG once
utility for patients remains the overarching governing goal.32
Accordingly, we will give major emphasis on patient short- and
long-term outcomes rather than costs, but comments on avoiding
redundant, poorly informative or useless testing will also be
provided to prevent futile costs. Clinical utility implies analytical
validity (in terms of precision or reproducibility and accuracy)
and clinical validity (in terms of sensitivity, speciﬁcity, positive
[PPV] and negative predictive values [NPV]) as applied to the
various populations under study. The level of some hemostatic
factors may be inﬂuenced by physiologic conditions. For
example, VWF and FVIII activity increases with age,33,34 but
without leading to a mitigation of symptoms.35 In women, VWF
levels vary during the phase of menstrual cycle36 and increase in
association with hormonal therapy and during pregnancy
(particularly in VWD type 1).37,38 In these instances, the lowest
historical VWF is assumed for diagnosis, but the actual level
should be considered for individualizing the replacement
treatment. Moreover, normal ranges in the ﬁrst year of life are
different from adults, and in toddlers may be inﬂuenced by recent
infections or by the transient occurrence of a weak lupus
anticoagulant or acquired FXII deﬁciency that may disappear
over the years, resulting in undue alarming prolongation of the
APTT. Finally, subjects with blood group O have lower VWF
levels, but it remains unknown if this has a clinical effect on
patients with established VWD. In summary, all these factors
inﬂuence the clinical utility of tests and deserve a critical
consideration.
Currently, an extensive search for underlying genetic muta-
tions is possible using high throughput sequencing facilitated by
commercial or institutional platforms with a growing list of
genes,39 but the IWG does not support a blind genetic search for
putative mutations outside the research setting. The IWG noted
that presently very few genetic tests meet clinical utility criteria. In
particular, for some MBD, like inherited platelet disorders, a
combination of clinical and laboratory criteria may be sufﬁcient
for a conclusive diagnosis. For others, genotyping is not
mandatory but may be advisable, for instance because a
genotype/phenotype correlation has been established. For a
few cases, when the clinical and laboratory picture is disorienting,
functional alterations are heterogeneous, or characterization is
uncertain, because too few cases have been described (eg, GT
variants, cPLA2 deﬁciency) genotyping may be recommended.
40
Exceptions may be cases of particularly difﬁcult diagnostic
classiﬁcation, where an exact diagnosis has practical implications
such as in the differential diagnosis of mild hemophilia A vs VWD
type 2N inmales, hemophilia A carrier status vs. VWD type 2N in
females, VWD type 2B vs platelet-type (pseudo) VWD41 or in
some inherited thrombocytopenias. In the most frequent form of
inherited thrombocytopenia, MYH9-related disease, speciﬁc
MYH9 variants can predict the likelihood of severe bleeding,
renal disease and deafness.42 In some other instances, molecular
diagnosis may help to identify thrombocytopenias responsive to a
thrombopoietin receptor agonist (TPO-ra).43 However, genetic
testing raises serious ethical, legal and social implications, since
results may cause stigmatization, family discord, and psychological
distress and should be performed with particular caution and with
the highest standards of informed consent and privacy. Access to
healthcareproviders speciﬁcally trained to interpret results of genetic
testing and to convey appropriate counseling should be offered.
Particular attention to these issues should be paid when genetic
testing and counseling apply to children.44,45This is particularly true
in some conditions like for example familial thrombocytopenias
with ANKRD26, RUNX1, ETV6mutations that may predispose to
hematologic malignancies or herald evolution into bone marrow
failure (MPL andMECOMmutations).26 In these instances, clinical
utility of diagnosis remains contentious, given the fact that currently
no treatment is available for these patients and as not all affected
patients will develop leukemia, and might have a negative impact,
particularly in children.46
Under these premises, the IWG agreed that a multi-stage
standardized diagnostic approach could be a more useful and
effective strategy to investigate most patients, reserving contex-
tualized approaches for speciﬁc situations such as those
mentioned previously.
Proposal for a systematic diagnostic
procedure
General criteria for initiating multistage laboratory
investigation
The underlying rationale for the proposed diagnostic strategy
(Fig. 1) is dual: to have sufﬁcient sensitivity (and NPV) to avoid
missing patients at risk of future bleeding, who may beneﬁt from
speciﬁc treatments; at the same time, to have sufﬁcient speciﬁcity
(and PPV) to spare healthy subjects further clinical or laboratory
testing.
Positive and negative outcomes for the individual patient of a
speciﬁc diagnosis ofMBD need consideration when initiating any
extensive investigation (Table 5). The IWG agreed that it is useful
to perform a standard screening (APTT, PT/INR and platelet
count) before moving to ﬁrst-stage investigation and further.
These simple tests could either conﬁrm previous results, or point
out incidental ﬁndings not bearing a risk of bleeding, like
pseudothrombocytopenia or defects in some contact phase
clotting factors or the presence of a transient lupus anticoagulant.
The multi-stage investigation should generally be reserved for
patients with a pathologic bleeding phenotype or in whom
standard screening reveals relevant abnormalities.
Traditionally, pathologic bleeding phenotype is assessed by
history-taking. However, in the absence of universally accepted
criteria for a standardized bleeding history, the IWG proposed
the use of the ISTH-BAT as the main reference standard to
identify subjects deserving multistage investigation, based on a
factor for bleeding in subjects not meeting the criteria for a bleeding phenotype qualifying for a MBD. In speciﬁc circumstances, in case of doubtful bleeding history in
young people undergoing surgery (e.g., tonsillectomy) or other hemostatic challenges, the presence of low VWFmay guide speciﬁc replacement therapy. Standard
platelet aggregometry (LTA) is imperfect and technically challenging but remains the best screen available for a mild/moderate inherited platelet disorder. Quality
assurance testing and use of a standardized battery of agonists are critical. Where available, lumi-aggregometry may be preferred because rare platelet disorders
may have normal platelet aggregation, but abnormal granule release, like the Hermansky Pudlak syndrome; however the disease can be suspected by physical
examination.
F. Rodeghiero et al. Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: A EHA Consensus Report
8
global bleeding score above a decisional threshold. To overcome
some limitations, patients with nuisance bleeding, as deﬁned in
Table 4, were also included in the multistage investigations
considering that they would not be captured by the ISTH-BAT,
which scores the severity and not the frequency of bleeding. In
addition, the IWG recognized that the deﬁnition of an abnormal
bleeding phenotype lies ultimately in the subjective judgment of
an expert clinician, integrating the many confounding factors,
such as the age of the subject and age at ﬁrst non-trivial bleeding,
comorbidities such as hypertension, number of previous
hemostatic challenges, recall biases, or the presence of other
family members with bleeding. Acquired conditions should be
excluded upfront. The discussion here is limited to standard
screening and ﬁrst-stage examination. Discussion on second-
stage investigations will be deferred to the evidence-based
disease-speciﬁc guidelines, which might lead to modiﬁcations/
integrations of the multistage approach here proposed.
The clinical utility of global tests including thromboelastog-
raphy on whole blood or platelet-rich plasma, measurements of
thrombin potential/generation.47,48 platelet function analyzer
(PFA)-100 and the skin bleeding time49,50 remains unestablished
and these tests were not considered appropriate to direct further
investigations.
Critical aspects in the use of ISTH-BAT in decision
making
In the ISTH-BAT, a cumulative score is obtained by summing the
worst ever recorded score for each symptom (Table 3). Thresh-
olds can be set at variable sensitivity (rate of detection of patients
with a bleeding disorder requiring investigation, true positive
rate) and speciﬁcity (rate of healthy people who are correctly
identiﬁed as not needing investigation, true negative rate). In this
way, standardization and comparison of different studies is
facilitated. The cumulative score will serve as a proxy
representation of the overall severity of bleeding phenotype. It
is reasonable to assume that the severity of the bleeding history
and the accumulated outcomes with hemostatic challenges
correlate with the bleeding risk. This is in keeping with the
ﬁndings of two major studies but not invariably demonstrated. In
a 1-year prospective study in 769 patients with various types of
VWD, a bleeding score >10 was the only independent predictor
of the need for future treatment with DDAVP or concentrates.51
Moreover, the ISTH BAT has been demonstrated to be highly
predictive of postsurgical bleeding for patients with inherited
platelet disorders, with an ISTH BAT ≥6 associated with strongly
increased bleeding risk.52 On the other hand, it should be pointed
out that in some studies no differences in bleeding score have been
found between patients with and without an established
MBD.4,53 Anyway, it appears that the cases missed by the
ISTH-BAT would have been detected by the standard screening
and ﬁrst-stage examination, as described in Figure 1. In this
regard, under the assumption that any test is justiﬁed by patients’
clinical utility, the aim of the BAT is not to demonstrate a strict
correlation between any identiﬁable BD and bleeding score, but
to include in the diagnostic process those individuals that could
beneﬁt from being identiﬁed as having a signiﬁcant risk of future
bleeding (sensitivity), while maintaining a high degree of
speciﬁcity.
Other quantitative BATs have been proposed, with slightly
different scales,54 or adapted to a pediatric population,55 or in a
condensed form;56 all are derived from a model initially
established in obligatory carriers of type 1 VWD, also known
as the Vicenza Bleeding Questionnaire.57 Critical reviews have
been published.16,58 In particular, a recent systematic review on
the diagnostic accuracy of various BATs showed that speciﬁcity
and sensitivity greatly varied, offering limited diagnostic value to
the work up of patients referred for bleeding evaluation in clinical
practice.59 However, this analysis cannot demonstrate if the cases
not captured by the ISTH-BAT were of clinical importance or
would not have been detected by standard screening, which we
propose to be applied to all referred patients (Fig. 1). Notably,
both the ISTH-BAT (symptoms scored from 1 to 4) and the
MCMDM-1VWD BAT (symptoms scored from 1 to 4, used in
wide European series of studies)54 yielded the same cumulative
score values at the 2.5 percentile of the normal population (0–3
for males, 0–5 for females, 0–2 for children), as shown by an
extensive study in 500 healthy individuals of different ages.60
Accordingly, this information can now be used to objectively
assess bleeding symptoms as “normal” or “abnormal”. There-
fore, the cut-off for a positive or abnormal bleeding score is ≥4 in
adult males, ≥6 in adult females and ≥3 in children, and is
associated with a speciﬁcity of 97.5%.60 The bleeding score was
the same in males and females, once menorrhagia and post-
partum bleeding were excluded. The IWG proposed the adoption
of these decisional limits in future studies and in clinical practice
as sufﬁcient to qualify a bleeding phenotype as worthy of
multistage investigation. In this way, subjective judgment is at
least partially overcome. In a prospective study of patients
referred for bleeding history to a tertiary center, using an
abbreviated ISTH-BAT, a score ≥4 proved to have high
speciﬁcity (0.81) and acceptable sensitivity (0.41) with NPV%
Table 5
Positive and Negative Outcomes for the Patient after Extensive Investigations for the Speciﬁc Diagnosis of a MBD
Expected positive outcomes Potential negative outcomes
Reassurance that the case was completely investigated Stigmatization, unnecessary concern and exaggerated perception of bleeding risk, particularly if a speciﬁc
diagnosis cannot be achieved (eg, BUC)
More precise assessment of future risk of bleeding Undue limitations in job, leisure or sport activities. Negative disposition toward pregnancy
Speciﬁc instructions for replacement therapies,
desmopressin and antiﬁbrinolytics and their use for
prevention and control of bleeding
Unnecessary use of replacement therapies
Tailored information and education regarding lifestyle,
avoidance of hemostasis-interfering drugs, job-related
risks, women’s issues, preparation to dental or surgical
procedures
Improper delay of dental or surgical procedures
Facilitated genetic counseling and targeted investigation of
family members
Risk of incorrect or provisional assignment to a diagnosis. Unexpected genetic variance
(2019) 3:5 www.hemaspherejournal.com
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of 99.3 and 84.5 in a clinical setting of low (1%) or moderate
(20%) prevalence and was signiﬁcantly and independently
associated with the presence of an odds ratio of MBD of
6.6.61 In clinical practice, to increase the sensitivity of ISTH-BAT,
we recommend that patients with any grade ≥1 bleeding at very
young age or with a history of infancy-speciﬁc bleeding
symptoms (as speciﬁed in the footnote to Table 3) are routinely
investigated. These symptoms greatly contributed to the
classiﬁcation of the severity of bleeding phenotypes in a pediatric
population with VWD62 and their occurrence in infancy requires
detailed investigation independently from the overall score of the
ISTH-BAT. Patients with nuisance bleeding, independent of the
ISTH-BAT score, also deserve multistage laboratory investiga-
tion. However, this standardized approach might be fallacious,
particularly in young people or in subjects with few hemostatic
challenges in their history, so that a sound clinical judgment can
never be omitted.59
Tailored approaches
Different contexts might require a tailored approach and a
different hierarchy of laboratory tests. In investigating the
relatives of an index case with a known disorder, often a single
speciﬁc measurement or the detection of a speciﬁc mutationmight
be sufﬁcient and the application of the ISTH-BAT would be
adjunctive, serving primarily to more precisely deﬁne individual
bleeding risk. In emergency situations, the hematologist should
switch to an immediate diagnostic approach to exclude acquired
BDs (eg, acquired hemophilia) or inherited disorders that could
have been missed (eg, FXIII deﬁciency, VWD or platelet
disorders). Examples are major bleeding after surgery or post-
partum, disproportionate bleeding after a minor hemostatic
challenge, profuse bleeding during pregnancy (once major
obstetric causes of bleeding have been excluded). Finally, in
some adults the bleeding history remains of dubious signiﬁcance,
as in patients already exposed to hemostatic challenges with
inconsistent bleeding manifestations. In these cases, we endorse
the time-honored practice suggested more than three decades ago
by the late Rapaport,63 that normality of minimal screening
including APTT, PT/INR (performed with a sensitive reagent
capable of detecting factors concentration below 40–50%) and
platelet count might be sufﬁcient to exclude major hemorrhages.
Limiting investigation to a few essential tests will generally
exclude the most severe congenital or acquired BDs. However,
for high-risk surgery, second-stage tests are advisable. Unselected
coagulation testing with the goal of assessing bleeding risk prior
to surgery in healthy subjects, although widely practiced, is
discouraged on the basis of a systematic literature search.64
General principles of management
Counseling and patients’ education
It is of critical importance that treating physicians provide
information on the various steps of investigation and on the ﬁnal
diagnosis to patients. The beneﬁts of the diagnostic outcome
should be maximized and the possible negative consequences
openly addressed (Table 5). This goal can be achieved only with a
complete and understandable communication. The concerns of the
individual and/or family members should always be taken into
consideration and addressed in a supportive and non-directive/
objective manner. The relationship between bleeding history,
laboratory or genetic testing and future risk of bleeding should be
clariﬁed and integrated and should constitute the basis for
personalized counseling and education. Adults with a bleeding
history of dubious signiﬁcance and normal screening tests should
be suggested to avoid a liberal use of drugs interfering with
hemostasis and reassured that unexpected bleeds could be easily
managed with tranexamic acid and/or local procedures. Of note,
patients with MBD are not exempted from thrombosis so that
antithrombotic agents may be required, making an assessment
between risks and beneﬁts very difﬁcult even to experts, due to the
complete lack of any evidence. Second-stage investigations are
always recommended in case of high risk surgery.63 Depending on
the speciﬁc diagnosis, information on available treatments
including antiﬁbrinolytic agents, desmopressin, platelet transfu-
sion, TPO-ra, recombinant activated FVII, and replacement
therapies should be provided. Detailed instructions should include
measures for prevention or control of spontaneous bleedings such
as epistaxis or gum bleeding and at-risk situations, like dental and
surgical procedures or traumatic events. Issues speciﬁc for women
(menarche, menstruation, pregnancy) may be of particular
importance as discussed in the dedicated section. In case of
bleeding after surgery or other hemostatic challenges treated
outside the reference center, patients should be instructed to
provide feedback to reevaluate the management. The IWG
recommends that pedigree investigation with conventional
laboratory tests or genetic tests is discussed with the index case.
In general, the IWG advises against pervasive genetic testing in
clinical practice, apart from targeted exceptions. In some cases,
ethical, legal, and social considerations may arise, requiring the
assistance of an expert ethicist.
Bleeders of unknown cause
These patients are at permanent risk of bleeding and pose serious
difﬁculties in counseling and management. Currently, very little is
known about their long-term outcomes. The IWG recommends that
these patients are treated as if they have a true BD and not dismissed
by minimizing their disorder, offering them continued surveillance
and assistance. They should be instructed on the use of
antiﬁbrinolytics or desmopressin (effective in 90% of cases during
minor or major hemostatic challenges65) and avoidance of drugs
interferingwith hemostasis.On the other hand, the IWGagreed that
patients with BUC should be reassured since it is unlikely that they
have an overlooked severe BD using the proposed multistage
approach. The IWG strongly recommends that future clinical,
laboratory and genetic research should be devoted to better
understand the pathogeneticmechanismandnatural courseof BUC.
Women’s issues
Bleeding issues in female include heavy menstrual bleeding (HMB),
ovulation bleeding, excessive and prolonged bleeding after miscar-
riage and primary and secondary post-partum hemorrhage (PPH).
HMB is a common problem; in a European survey 27% of 4506
women reportedHMB,ofwhom15%requiredmedical attention.66
MBDs (in particular VWDandplatelet function disorder) have been
shown to be the underlying cause in up to 20% of women with
HMB.67 PPH, which complicates 5% of deliveries, is often multi-
factorial (70% of cases), with uterine atony being the commonest
cause. Ovulation bleeding of little clinical signiﬁcance or occasion-
ally associated with some mid-cycle pain is also common in healthy
women -but inwomenwithMBDssuchasVWDitmaybe recurrent
or rarely occur as a major bleeding complication. Therefore, testing
all such women is not feasible and unnecessary. However, every
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woman with excessive bleeding should have a risk assessment for
underlying BDs. The severity of HMB and of primary or secondary
PPHmay be difﬁcult to assess quantitatively, particularlywhen they
present after the initiationofhormonal therapyorduringpregnancy.
In fact, hormones and pregnancy may mask the diagnosis of a
bleeding disorder falsely elevating clotting factor orVWF levels. The
relativelyhighvaluesmaydrop tobasal levels afterparturitionwitha
risk of bleeding.Decisional thresholds of clotting factors/VWF levels
for replacement therapy or reevaluation of diagnosis should be
considered. Thus, the value of a thorough past bleeding history and
of a family history of bleeding (and historical coagulation factors/
VWF levels) cannot be over-emphasized and are the essential tools
for presumptive diagnosis. ISTH-BAT criteria and the proposed cut-
off of ≥6 (Fig. 1) remain valid for symptoms manifested before the
initiationofhormonal therapyprescribed forbleeding.However, the
monthly occurrence of annoying bleeding might impact the QoL of
some women and ﬁt the deﬁnition of nuisance bleeding, thus
demanding a full investigation regardless to overall ISTH-BAT
score. Similarly, isolated severe gynecological bleeding such asHMB
since menarche or acute episodes of HMB or ovulation bleeding
requiring hospital admission warrants full investigations for BDs.
HMB and postpartum bleeding are experienced by up to 80%
of women with non-severe VWD.68,69 Despite replacement
therapy at parturition, factor levels drop down rapidly with
higher blood loss than in normal women.70 The bleeding score
predicts clinical outcomes,70 but its role in predicting response to
replacement therapy, as in non-pregnant individuals,51 is not
known. It is critical to have a multidisciplinary approach for
management with close collaboration with the obstetric/gynecol-
ogy team and to recognize that the presence ofMBD does not rule
out the possibility of coexisting gynecological problems. Since
ﬁrst line or single therapy is often not effective for managing
HMB in women with BDs, combination therapy including
hormonal and antiﬁbrinolytic therapies as well as DDAVP or
factor replacement should be considered. In women of
reproductive age, a high index of suspicion for iron deﬁciency
(which may impact on QoL) should lead to screening total iron
binding capacity (TIBC) and/or ferritin, even when hemoglobin is
normal.71 For women in families with hemophilia, pedigree
analysis and genetic counseling and diagnosis are important for
decision-making in relation to reproduction and understanding
options for prenatal diagnosis before ﬁrst pregnancy. The risk of
fetal bleeding is minimal with MBD. Management of labor and
mode of delivery should be discussed with the mother and
planned in advance; precautions should be taken to minimize the
risk of fetal trauma during labor and delivery.
Conclusions
In the absence of general evidence-based outcomes on which to
make operative decisions and in the lack of standardized and
harmonized deﬁnitions, the IWG worked to maximize consensus
by proposing clinically relevant deﬁnitions, and well-grounded
objectives for the investigation of subjects suspected of having a
MBD. The strength of the proposal lies in the unanimous panel
consensus. This construct has several purposes. First, it proposes
a general diagnostic approach to distinguish normal subjects
from individuals with a pathologic bleeding tendency, primarily
based on a standardized quantitative assessment of the bleeding
history. Second, amultistage laboratory approach is proposed for
patients with a qualifying phenotype, from standard screening to
more speciﬁc laboratory or genetic studies. This approach awaits
conﬁrmation from the analysis of the subsequent disease-speciﬁc
evidence-based guidelines. However, the IWG recognizes that
some individuals will ultimately not receive a speciﬁc diagnosis
(BUC), despite a qualifying bleeding phenotype and a full
investigation. The IWGproposes this construct to serve as a guide
for future development of guidelines speciﬁc for distinct MBDs,
under the overarching principle of clinical utility.
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